Literature DB >> 2687071

[Hepatitis caused by clometacin (Dupéran). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis?].

E A Pariente1, A Hamoud, D Goldfain, J P Latrive, J Gislon, P Cassan, T Morin, J L Staub, J P Ramain, J L Bertrand.   

Abstract

Thirty cases of clometacin-induced hepatitis were retrospectively collected over a nine-year period in hepatogastroenterological units of non university, public hospitals. There was a strong female predominance (90 percent). Clometacin (Dupéran) was taken because of arthritis in 8 out of 10 cases. Administration was continuous in 85 percent of cases and median duration was 445 days. median dose was 450 mg per day. Jaundice, fatigue, and weight loss were the most frequent symptoms, but edema, ascites and palmar erythema were not uncommon. Thrombopenia (38 percent) was the most frequent hematologic abnormality. Renal failure, always with benign course, was present in 1/4 of cases. Biochemical disorders indicated hepatocellular and cholestatic hepatitis in 3/4 and 1/4 of cases respectively. Hypoprothrombinemia below 50 percent was noted in 1 out of 6 cases, and was associated with death in half cases. Gamma-globulins were increased in 80 percent of cases, with a predominant increase of IgG. Antinuclear or anti-smooth muscle antibodies were present in 60 percent of cases, whereas antimitochondrial and antimicrosomes were absent. Histopathological examination of the liver biopsy specimens obtained in 25 patients showed acute hepatitis in 8 and chronic active hepatitis with fibrosis in 17--including 6 patients with cirrhosis; there were no epidemiological, clinical (except ascites), or biochemical differences between these two groups. Four of the 7 patients tested had HLA B8 antigens; they all had chronic active hepatitis, with autoantibodies in 3 cases. Median duration of hospitalization was 21 days. Hepatitis was directly responsible for death in 3 patients; biochemical sequelae (hypergammaglobulinemia or anicteric cholestasis) were present in 8 patients, 2 of whom most likely had cirrhosis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2687071

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  7 in total

1.  Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction.

Authors:  Omar Khokhar; Christopher Gange; Stephen Clement; James Lewis
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

2.  HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin.

Authors:  M Kurosaki; H Takagi; M Mori
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

Review 3.  Drug-induced "allergic hepatitis".

Authors:  P Podevin; M Biour
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

4.  In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers.

Authors:  Ana Alfirevic; Faviel Gonzalez-Galarza; Catherine Bell; Klara Martinsson; Vivien Platt; Giovanna Bretland; Jane Evely; Maike Lichtenfels; Karin Cederbrant; Neil French; Dean Naisbitt; B Kevin Park; Andrew R Jones; Munir Pirmohamed
Journal:  Genome Med       Date:  2012-06-25       Impact factor: 11.117

Review 5.  Drug-induced autoimmune-like hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-02-16       Impact factor: 3.487

6.  Development of Autoimmune Hepatitis during Direct-acting Antiviral Therapy for Chronic Hepatitis C Virus Infection.

Authors:  Kotaro Matsumoto; Kentaro Kikuchi; Yusuke Kajiyama; Yuichi Takano; Masatoshi Mabuchi; Shinpei Doi; Koichiro Sato; Hiroshi Miyakawa; Ichiro Yasuda
Journal:  Intern Med       Date:  2018-04-27       Impact factor: 1.271

Review 7.  Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice.

Authors:  Marina Villanueva-Paz; Laura Morán; Nuria López-Alcántara; Cristiana Freixo; Raúl J Andrade; M Isabel Lucena; Francisco Javier Cubero
Journal:  Antioxidants (Basel)       Date:  2021-03-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.